Biotechnology Companies in Ireland

Through pioneering life science and artificial intelligence, we developed our unique Nuritas MagnifierNπΦ platform that allows us to identify, unlock, clinically test and patent peptides; turning them into powerful and precise ingredients that elevate natural efficacy. We want to empower people to live healthier lives, naturally by making our everyday products healthier, safer, greener and more efficacious. From what we eat, to what we apply to our skin. By translating nature’s wisdom into innovation, together, we can change the life of billions.

Alkermes focuses on the development of innovative medicines that seek to address unmet needs of people living with serious mental illness, addiction, and cancer. As a fully-integrated, global biopharmaceutical company, we apply our scientific expertise and proprietary technologies to develop products that are designed to make a meaningful difference in the way patients manage their disease. We are inspired by some of the most pressing public health challenges of our time to help advance innovation with the potential to improve treatment options and outcomes for patients. Beyond our important mission of developing medicines, we believe it is our responsibility to take a holistic approach as we seek to support patients, caregivers, and broader impacted communities. In this context we also work to help support and enhance the systems through which these complex diseases are treated. We are committed to patient engagement, disease education and awareness, and advocacy for important policies that support equitable access to quality treatment. Headquartered in Dublin, Ireland, we have an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. See our Community Guidelines: https://www.alkermes.com/social-community-guidelines

Deciphex is focused on the development of software applications for preclinical/toxicologic pathology that improve productivity and help pathologists focus on the critical content. The pathology industry is beset with increasing caseload and diagnostic complexity, against a globally declining number of pathologists to service the workload. We believe that digital pathology combined with computer aided diagnostic tools will help make pathologists work more efficiently in the future, and offers a solution to the pending crisis in supply/demand in pathology services.

GlowDx is developing the Worlds First True Point-of-Care (POC) Diagnostics Platform, aimed at tackling Infectious Disease in Emerging Economies. Our first test detects mosquito-bourne infections (Dengue Fever, Chikungunya & Zika Virus), while our AI utilizes machine learning to model & predict future outbreaks.

Our Vision: Our intelligent sensing platforms integrated on all plasma and RF processing equipment to enable atomic-scale engineering for the advancement of nano-technology. Our Mission: Creating intelligent sensing platforms for advanced plasma and RF manufacturing processes, to improve process performance and reduce product scrap. Our Purpose: Our company exists because we believe in the science of measurement. We believe that accurate process measurement is critical for the future of nano-scale manufacture, where process stability and repeatability are paramount to delivering the technology of the future. We measure parameters and processes under some of the most extreme environments encountered on earth. We measure things often considered impossible. #MeasuringTheImpossible. Our value proposition is that we provide you with an independent diagnosis of your process health, using intelligent, network-enabled sensing platforms, in conjunction with our vast experience in RF and plasma systems, to help you solve the most complex processing issues.

FIRE1 aims to improve patient quality of life, and patient outcomes, while lowering overall healthcare costs.

Electrical Impedance Tomography is a non-invasive, radiation-free imaging modality. Kite Medical is developing a novel device to detect kidney reflux in children. The non-invasive diagnostic solution for kidney reflux removes the trauma and the need for complicated procedures and a hospital visit. Kidney reflux is the most common urological disorder in childhood, affecting up to three per cent of young children. It is most prevalent from six months to five years of age. The condition may resolve as the child gets older, but left undiagnosed and untreated it can lead to permanent kidney damage and ultimately to kidney failure. Early diagnosis is vital, but current standard tests involve catheterisation, filling the bladder with contrast agent and multiple xray images. The Kite solution is a cost-effective, patient centric alternative, non-invasive and radiation-free ideal for screening and monitoring of these patients.

GH Research is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.

Luminate Medical is a healthcare technology company that builds devices to prevent and control the side effects of cancer treatment. Based in Galway, Ireland, Luminate is pioneering the development of Lily, a device to prevent chemotherapy induced hair loss in a comfortable and portable way, and Lilac, the world's first preventative treatment for peripheral neuropathy. Luminate is a VC-backed startup funded by Y Combinator (S21) with multiple successful grant and investment rounds to date.

Mainstay Medical, led by a team of dedicated scientists, executives, engineers, and clinical experts, brings to you ReActiv8®, the first and only FDA-approved restorative treatment for mechanical chronic low back pain. RESTORE Control RESTORE Function RESTORE Stability ReActiv8 LIFE The Company was incorporated in Dublin, Ireland and headquartered in San Diego, CA. It has subsidiaries operating in Ireland, the United States, Australia, Germany and the Netherlands.

Carrick Therapeutics is pioneering a portfolio of unique, first in class, cancer treatments that target driver mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient’s tumour. Targeting the molecular pathways that drive the most aggressive and resistant forms of cancer will transform the way that cancer is treated and have a major impact on the lives of cancer patients. By linking a network of clinicians and scientists in internationally leading research institutes and hospitals, Carrick will streamline the introduction of these ground-breaking cancer therapies into the clinic, thus serving cancer patients around the world.

Avadel (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. We are disrupting paradigms where it’s needed most – starting with narcolepsy. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. At Avadel, our core values foster an atmosphere of transformation and collaboration. In everything we do, we consider the patient experience, listening to their needs as we pursue the development and delivery of medicines that will transform the treatment landscape and have the greatest impact on people living with sleep disorders. Learn more about us at www.avadel.com and follow us on Twitter at @AvadelPharma.